BFM
DNA icon

Boothbay Fund Management’s Ginkgo Bioworks DNA Stock Holding History

Boothbay Fund Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,534
Closed -$117K – 1526
2025
Q1 		$117K Buy
+20,534
New +$209K ﹤0.01% 1218
2024
Q4 		– Sell
-66,030
Closed -$566K – 1592
2024
Q3 		$538K Buy
66,030
+60,149
+1,023% +$603K 0.01% 950
2024
Q2 		$78.6K Buy
5,881
+4,906
+503% +$146K ﹤0.01% 1372
2024
Q1 		$45.2K Buy
975
+225
+30% +$11.6K ﹤0.01% 1479
2023
Q4 		$50.7K Sell
750
-143
-16% -$8.76K ﹤0.01% 1522
2023
Q3 		$64.7K Buy
893
+11
+1% +$879 ﹤0.01% 1608
2023
Q2 		$65.6K Hold
882
– – ﹤0.01% 1659
2023
Q1 		$46.9K Buy
882
+257
+41% +$16.3K ﹤0.01% 2027
2022
Q4 		$42.3K Buy
+625
New +$57.5K ﹤0.01% 1888
2022
Q3 		– Sell
-850
Closed -$81K – 2318
2022
Q2 		$81K Sell
850
-5,160
-86% -$629K ﹤0.01% 2019
2022
Q1 		$969K Buy
6,010
+5,610
+1,403% +$1.09M 0.02% 927
2021
Q4 		$133K Buy
+400
New +$190K ﹤0.01% 1647

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Boothbay Fund Management's DNA Position: Q2 2025 in Review

Boothbay Fund Management sold out of Ginkgo Bioworks (DNA) in Q2 2025, closing a stake of 20,534 shares — an estimated $117K sold.

Boothbay Fund Management first reported a position in DNA in Q4 2021 and held it in 12 quarters. The position peaked at $969K in Q1 2022. 166 funds tracked by Wall St. Rank hold DNA as of Q2 2025.

  • Boothbay Fund Management reported no remaining Ginkgo Bioworks position as of Q2 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 20,534 Ginkgo Bioworks shares in Q2 2025, an estimated $117K.
  • Boothbay Fund Management first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 12 quarters.
  • Boothbay Fund Management's Ginkgo Bioworks position peaked at $969K in Q1 2022.
  • 166 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.